We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Chemomab Therapeutics Ltd | NASDAQ:CMMB | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.016 | 1.65% | 0.9849 | 0.87 | 1.34 | 0.9849 | 0.93 | 0.93 | 24,519 | 05:00:02 |
From Jul 2022 to Jul 2024
TEL AVIV, Israel, April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2–May 4, 2023. Chemomab management will present a corporate overview on Wednesday, May 3, 2023.
Aegis 2023 Virtual Investor Conference
Date: | May 3, 2023 |
Time: | 9:00am EDT |
Venue: | Virtual |
Format: | Webcast -- Corporate overview |
Presenter: | Senior management |
Webcast Link: | https://us02web.zoom.us/j/81590540881 |
Information: | mschiavellojr@aegiscap.com |
In addition, Chemomab reported that its corporate development team will be in Boston June 5-8, 2023, participating in the BIO International Convention's One-on-One Partnering™ event. Registered attendees can click here to log in and schedule a meeting with Chemomab.
About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com.
Contacts: | |
Investors: | Investors & Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1 (917) 734-7387 | Consulting Vice President, Investor & Public Relations |
ir@chemomab.com | Strategic Communications |
barbara.lindheim@chemomab.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-2023-aegis-virtual-conference-301807799.html
SOURCE Chemomab Therapeutics, Ltd.
Copyright 2023 PR Newswire
1 Year Chemomab Therapeutics Chart |
1 Month Chemomab Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
